SOBI reveals strong sales in third quarter
Swedish Orphan Biovitrum (STO: SOBI) has published its third quarter results revealing that total revenues were 517.3 million Swedish kronor ($81.1 million), an increase of 12% from the same quarter last year at 463.8 million kronor.
Product revenues were 393.5 million kronor, up from the same quarter last year of 306.4 million kronor. Earnings per share were -0.21 kronor, showing a 24% decrease from -0.17 kronor last year.
Geoffrey McDonough, chief executive and president, said: “The third quarter for Sobi demonstrated solid progress in operational performance, business development, and in the advancement of our pipeline. Revenue for the overall portfolio grew by 12% compared to last year, with Kineret and Partner Products showing strong performance in the quarter. Our margins are evolving as expected and we are making good progress financially with a stable cash position and improved profitability from operations.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze